<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-1249</journal-id>
<journal-title><![CDATA[Archivos de Pediatría del Uruguay]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Pediatr. Urug.]]></abbrev-journal-title>
<issn>1688-1249</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Uruguaya de Pediatría]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-12492025000101203</article-id>
<article-id pub-id-type="doi">10.31134/ap.96.3</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Derivados de cannabis medicinal en el tratamiento de niños, niñas y adolescentes con epilepsia refractaria asistidos en un centro de referencia de Uruguay, entre 2021-2024. Perfil de uso, beneficios y riesgos]]></article-title>
<article-title xml:lang="en"><![CDATA[Medicinal cannabis derivatives in the treatment of children and adolescents with refractory epilepsy assisted in a reference center in Uruguay between 2021-2024. Usage profile, benefits and risks]]></article-title>
<article-title xml:lang="pt"><![CDATA[Derivados medicinais da cannabis no tratamento de crianças e adolescentes com epilepsia refratária atendidos em um centro de referência no Uruguai entre 2021-2024. Perfil de uso, benefícios e riscos]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[Irene]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Notejane]]></surname>
<given-names><![CDATA[Martín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Speranza]]></surname>
<given-names><![CDATA[Noelia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Galarraga]]></surname>
<given-names><![CDATA[Florencia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vergara]]></surname>
<given-names><![CDATA[María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Herrera]]></surname>
<given-names><![CDATA[Rodrigo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moreira]]></surname>
<given-names><![CDATA[Florencia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gregorini]]></surname>
<given-names><![CDATA[Valentina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Parada]]></surname>
<given-names><![CDATA[Paulina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Prego]]></surname>
<given-names><![CDATA[Francisco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[Ma. Noel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,UDELAR Facultad de Medicina Unidad Académica Farmacología y Terapéutica]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,UDELAR Facultad de Medicina Unidad Académica Pediatría B]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,UDELAR Facultad de Medicina Unidad Académica Farmacología y Terapéutica]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,UDELAR Facultad de Medicina Unidad Académica Farmacología y Terapéutica]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,UDELAR Facultad de Medicina Unidad Académica Métodos Cuantitativos]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,UDELAR Facultad de Medicina ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<volume>96</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-12492025000101203&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-12492025000101203&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-12492025000101203&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción: existe evidencia del uso de derivados de cannabis medicinal (DCM) como alternativa terapéutica para la epilepsia refractaria (ER).  Objetivos:  describir el perfil de uso, beneficios y riesgos de los DCM en el tratamiento de niños, niñas y adolescentes (NNA) con ER, asistidos en el Centro Hospitalario Pereira Rossell entre julio/2021 y febrero/2024.  Metodología:  estudio descriptivo, longitudinal, retrospectivo, mediante revisión de historias y entrevistas a familiares en dos momentos (t1: julio/2022 y t2: febrero/2024). Se incluyeron todos los NNA menores de 19 años que recibieron DCM. El beneficio se evaluó mediante reducción en frecuencia y duración de crisis epilépticas (CE). Se indagó acerca de eventos adversos y accesibilidad.  Resultados:  se incluyeron 15 NNA, mediana de 8 an&#771;os, 9/15 sexo masculino, 13/15 portadores de encefalopatías crónicas severas. Al inicio del tratamiento 12/15 utilizaba DCM de origen industrial. La mediana de dosis inicial fue 0,5 mg/kg/día, luego 3,5 y 3,7 mg/kg/día en t1 y t2, respectivamente. Todos los cuidadores reportaron reducción mayor a 50% en la frecuencia de CE y la mitad refirió reducción en la duración. Si bien la farmacia hospitalaria fue la vía más frecuente de obtención, la mayoría expresó dificultades de acceso. En ocho casos se identificaron efectos adversos, en su mayoría leves.  Conclusiones:  la mayoría de los NNA presentaron buena respuesta al tratamiento con DCM, que se mantuvo en el seguimiento. El perfil de seguridad fue adecuado. Se identificaron problemas de accesibilidad al tratamiento.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary:  Introduction:  there is evidence of the use of medicinal cannabis derivatives (DCM) as a therapeutic alternative for Refractory Epilepsy (RE).  Objectives:  describe the profile of use, benefits and risks of DCM in the treatment of children and adolescents (NNA) with RD, assisted at the Pereira Rossell Hospital Center between July/2021 and February/2024.  Methodology:  descriptive, longitudinal, retrospective study through review of histories and interviews with family members at two moments (t1: July/2022 and t2: February/2024). All children under 19 years of age who received DCM were included. The benefits were assessed according to the reduction in frequency and duration of epileptic seizures (EC). Adverse events and accessibility were researched.  Results:  15 children and adolescents were included, median age 8 years, 9/15 male, 13/15 carriers of severe chronic encephalopathies. At the beginning of treatment, 12/15 used DCM of industrial origin. The median initial dose was 0.5 mg/kg/day, then 3.5 and 3.7 mg/kg/day at t1 and t2, respectively. All caregivers reported a greater than 50% reduction in the frequency of CE and half of them reported a reduction in the duration of the crises. Even though the hospital pharmacy was the most frequent means of obtaining it, most of them expressed difficulties having access to it. Adverse effects, even though mostly mild, were identified in 8 cases.  Conclusions:  the majority of children and adolescents presented a good response to treatment with DCM, which was maintained during follow-up. The safety profile was adequate. Treatment accessibility problems were identified.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  há evidências do uso de derivados medicinais da Cannabis (DCM) como alternativa terapêutica para Epilepsia Refratária (ER).  Objetivos:  descrever o perfil de utilização, benefícios e riscos do MCD no tratamento de crianças e adolescentes (NNA) com DR, atendidos no Centro Hospitalar Pereira Rossell entre julho/2021 e fevereiro/2024.  Metodologia:  estudo descritivo, longitudinal, retrospectivo por meio de revisão de histórias e entrevistas com familiares em dois momentos (t1: julho/2022 e t2: fevereiro/2024). Todas as crianças menores de 19 anos que receberam DCM foram incluídas. O benefício foi avaliado segundo a redução na frequência e duração das crises epilépticas (CE). Eventos adversos e acessibilidade foram investigados.  Resultados:  foram incluídas 15 crianças e adolescentes, idade mediana de 8 anos, 9/15 do sexo masculino, 13/15 portadores de encefalopatias crônicas graves. No início do tratamento, 12/15 utilizavam DCM de origem industrial. A dose inicial mediana foi de 0,5 mg/kg/dia, depois 3,5 e 3,7 mg/kg/dia em t1 e t2, respectivamente. Todos os cuidadores relataram uma redução superior a 50% na frequência de EC e metade deles reportaram uma diminuição na duração das crises. Embora a farmácia hospitalar tenha sido o meio mais frequente de obtenção, a maioria manifestou dificuldades de acesso. Os efeitos adversos, principalmente leves, foram identificados em 8 casos.  Conclusões:  a maioria das crianças e adolescentes apresentou boa resposta ao tratamento com MCD, que se manteve durante o acompanhamento. O perfil de segurança foi adequado. Foram identificados problemas de acessibilidade ao tratamento.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Marihuana Medicinal]]></kwd>
<kwd lng="es"><![CDATA[Epilepsia Refractaria]]></kwd>
<kwd lng="es"><![CDATA[Niño]]></kwd>
<kwd lng="en"><![CDATA[Medical Marijuana]]></kwd>
<kwd lng="en"><![CDATA[Drug Resistant Epilepsy]]></kwd>
<kwd lng="en"><![CDATA[Child.]]></kwd>
<kwd lng="pt"><![CDATA[Maconha Medicinal]]></kwd>
<kwd lng="pt"><![CDATA[Epilepsia Resistente a Medicamentos]]></kwd>
<kwd lng="pt"><![CDATA[Criança]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Santis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Speranza]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso de cannabis medicinal en las epilepsias]]></article-title>
<source><![CDATA[Tend Med]]></source>
<year>2019</year>
<volume>28</volume>
<numero>55</numero>
<issue>55</issue>
<page-range>152-6</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[Cannabis recommendations]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Newmaster]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global trends in cannabis and cannabidiol research from the year 1940 to 2019]]></article-title>
<source><![CDATA[Curr Pharm Biotechnol]]></source>
<year>2021</year>
<volume>22</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>579-91</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Devinsky]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Cross]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Laux]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Marsh]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Nabbout]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>376</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2011-20</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Devinsky]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cross]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Villanueva]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Wirrell]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Privitera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2018</year>
<volume>378</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1888-97</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thiele]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Marsh]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[French]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mazurkiewicz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Benbadis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Joshi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4) a randomised, double-blind, placebo-controlled phase 3 trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2018</year>
<volume>391</volume>
<numero>10125</numero>
<issue>10125</issue>
<page-range>1085-96</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Scheffer]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Gunning]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gil]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Perry]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome a randomized clinical trial]]></article-title>
<source><![CDATA[JAMA Neurol]]></source>
<year>2020</year>
<volume>77</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>613-21</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thiele]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bebin]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bhathal]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Jansen]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Kotulska]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lawson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex a placebo-controlled randomized clinical trial]]></article-title>
<source><![CDATA[JAMA Neurol]]></source>
<year>2021</year>
<volume>78</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>285-92</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lattanzi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Brigo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cagnetti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Trinka]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Silvestrini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of adjunctive cannabidiol in patients with Lennox-Gastaut syndrome a systematic review and meta-analysis]]></article-title>
<source><![CDATA[CNS Drugs]]></source>
<year>2018</year>
<volume>32</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>905-16</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Borgelt]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Blackmer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol a new hope for patients with Dravet or Lennox-Gastaut syndromes]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>2019</year>
<volume>53</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>603-11</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Devinsky]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Thiele]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Appleton]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Harden]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2018</year>
<volume>90</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>e1204-11</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<source><![CDATA[Ley N° 19172. Regulación y control del cannabis. Montevideo, 7 de enero de 2014.]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[IMPO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<source><![CDATA[Ley N° 19847. Declaración de interés público las acciones tendientes a proteger, promover y mejorar la salud pública mediante productos de calidad controlada y accesibles, en base a cannabis o cannabinoides, así como el asesoramiento médico e información sobre beneficios y riesgos de su uso. Montevideo, 8 de enero de 2020.]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[IMPO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<source><![CDATA[Decreto N° 56/023. Montevideo, 27 de febrero de 2023.]]></source>
<year>2023</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[IMPO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<source><![CDATA[Decreto N° 298/017. Autorización de "venta bajo receta profesional" para las especialidades farmacéuticas con cannabidiol como principio activo. Montevideo, 24 de octubre de 2017.]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[IMPO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Listado de Medicamentos. Consulta de medicamentos]]></source>
<year>2024</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[MSP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Guido]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Morandi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Rivas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Vega]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso de derivados de cannabis medicinal en una población pediátrica en Uruguay durante 2019-2021]]></article-title>
<source><![CDATA[An Fac Med]]></source>
<year>2022</year>
<volume>9</volume>
<numero>^sS1</numero>
<issue>^sS1</issue>
<supplement>S1</supplement>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Santis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Galarraga]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Alcarraz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización y seguimiento de una población de uruguayos usuarios de derivados de cannabis medicinal artesanal]]></article-title>
<source><![CDATA[Rev Méd Urug]]></source>
<year>2023</year>
<volume>39</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Notejane]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zunino]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Speranza]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Giachetto]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bernadá]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Derivados cannábicos para uso medicinal en niños y adolescentes aportes para un uso responsable y seguro]]></article-title>
<source><![CDATA[Arch Pediatr Urug]]></source>
<year>2018</year>
<volume>89</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>187-93</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arias]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Glosario de medicamentos: desarrollo, evaluación y uso]]></source>
<year>1999</year>
<publisher-loc><![CDATA[Washington, D.C. ]]></publisher-loc>
<publisher-name><![CDATA[OPS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alvarado]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ivanovic]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherencia a tratamiento en la epilepsia una cuestión por resolver]]></article-title>
<source><![CDATA[Rev Méd Chile]]></source>
<year>2013</year>
<volume>141</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1085-6</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caraballo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Demirdjian]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Huaman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of cannabidiol in a prospective cohort of children with drug-resistant epileptic encephalopathy in Argentina]]></article-title>
<source><![CDATA[Seizure]]></source>
<year>2020</year>
<volume>80</volume>
<page-range>75-80</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Talwar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Estes]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Aparasu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Reddy]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Exp Neurol]]></source>
<year>2023</year>
<volume>359</volume>
<page-range>114238</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Treves]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Mor]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Allegaert]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bassalov]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Berkovitch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Stolar]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Sci Rep]]></source>
<year>2021</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>23462</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pawliuk]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chau]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Rassekh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[McKellar]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Siden]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of paediatric medicinal cannabis use A scoping review]]></article-title>
<source><![CDATA[Paediatr Child Health]]></source>
<year>2020</year>
<volume>26</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>228-33</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Funnell]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Heaney]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cable]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wheeler]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol oil ingested as sublingual drops or within gelatin capsules shows similar pharmacokinetic profiles in healthy males]]></article-title>
<source><![CDATA[Cannabis Cannabinoid Res]]></source>
<year>2024</year>
<volume>9</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>e1423-32</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hausman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Menascu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents an observational, longitudinal study]]></article-title>
<source><![CDATA[Brain Dev]]></source>
<year>2018</year>
<volume>40</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>544-51</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tzadok]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Uliel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Linder]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Menascu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CBD-enriched medical cannabis for intractable pediatric epilepsy The current Israeli experience]]></article-title>
<source><![CDATA[Seizure]]></source>
<year>2016</year>
<volume>35</volume>
<page-range>41-4</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCoy]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Mehmadi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kabir]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Alhadid]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome]]></article-title>
<source><![CDATA[Ann Clin Transl Neurol]]></source>
<year>2018</year>
<volume>5</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1077-88</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nixon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kerr]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Breheny]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Wild]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient Reported Outcome (PRO) assessment in epilepsy a review of epilepsy-specific PROs according to the Food and Drug Administration (FDA) regulatory requirements]]></article-title>
<source><![CDATA[Health Qual Life Outcomes]]></source>
<year>2013</year>
<volume>11</volume>
<page-range>38</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mohanraj]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Brodie]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Measuring the efficacy of antiepileptic drugs]]></article-title>
<source><![CDATA[Seizure]]></source>
<year>2003</year>
<volume>12</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>413-43</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Golyala]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kwan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug development for refractory epilepsy the past 25 years and beyond]]></article-title>
<source><![CDATA[Seizure]]></source>
<year>2017</year>
<volume>44</volume>
<page-range>147-56</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Grinspoon]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fleming]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Skirvin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wade]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wolper]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The long-term efficacy of cannabidiol in the treatment of refractory epilepsy]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2021</year>
<volume>62</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1594-603</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thiele]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bebin]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Filloux]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Kwan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Loftus]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sahebkar]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex an open-label extension trial]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2022</year>
<volume>63</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>426-39</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Adherencia a los tratamientos a largo plazo: pruebas para la acción]]></source>
<year>2004</year>
<publisher-loc><![CDATA[Ginebra ]]></publisher-loc>
<publisher-name><![CDATA[OMS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neale]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of cannabis for treating children with refractory epilepsy]]></article-title>
<source><![CDATA[Nurs Child Young People]]></source>
<year>2017</year>
<volume>29</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>32-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
